List of Artificial Intelligence Companies in Spain - 10

Our mission is to accelerate the transition to rational, computerized drug discovery via simulations and machine learning. To fulfill our vision, we work with our customers by becoming key technology partners, boosting their discovery workflow with the most innovative solutions. Science, research, innovation, and development are the founding pillars of our company.

AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.

Biorce is a medtech company based in Barcelona, Spain, founded in 2024. The company focuses on transforming the drug development process, particularly clinical trials, by utilizing artificial intelligence (AI). Biorce aims to make innovative drugs more affordable and accessible by enhancing the efficiency and speed of these trials. The company's mission is to reduce the cost of clinical trials by over 50% and decrease the time spent on them by more than 40%. Biorce achieves this by minimizing human error and streamlining the drug development cycle. One of its key products is Jarvis, a clinical AI assistant trained on over 500,000 studies, which provides access to clinical data and expert insights to support medical research and patient care. Biorce primarily serves the healthcare sector, focusing on pharmaceutical and biotech companies. The company has raised $3.68 million in funding and is currently in the seed VC stage, actively working to improve the efficiency and cost-effectiveness of drug development processes.

CONNECTA Therapeutics S.L. is a biotechnology company that develops new treatments for CNS unmet medical needs. The company is initially focus on the clinical development of a new “first-in-class” molecule for the treatment of fragile X syndrome (FXS). FXS is the most common cause of hereditary intellectual disability and there are no therapeutic interventions currently available. The molecule was discovered after evaluating more than 30 molecular and cellular targets. The molecule has been proven, in in vitro tests and in vivo in animal models, to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders (Rett syndrome, Down syndrome and autism spectrum disorders, among others).

Flomics is developing novel blood-based diagnostic tools for a broad range of complex diseases. Our proprietary technology accurately identifies pattern changes in the circulating long RNA molecules of patients. With deep learning algorithms we identify RNA changes associated with disease states in a faster, cheaper and non-invasive way.

Leanbio is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in Barcelona, founded in June 2014. The company specializes in the development and manufacturing of biologics, focusing on accelerating the time-to-market for New Biological Entities (NBEs) and biosimilars. Leanbio adheres to Quality-by-Design (QbD) principles and maintains regulatory compliance throughout its processes. The company offers comprehensive services across the biopharmaceutical product lifecycle, including feasibility studies, process development, analytical development, and manufacturing. Leanbio's capabilities encompass the production of therapeutic molecules such as antibodies and enzymes, as well as nucleic acids like mRNA and plasmid DNA. Their facilities include a 4,000 sqm GMP site in Barcelona, equipped for both microbial and mammalian production, and they have the capacity to handle high-potency products. Leanbio serves a diverse range of sectors, including pharmaceuticals, biotechnology, cosmetics, and agro-food, having supported over 100 therapeutic candidates in various stages of development. Their flexible platforms and regulatory expertise enable them to provide tailored solutions while minimizing intellectual property constraints for their clients.

Moirai Biodesign is a pioneering RNA design company developing a novel RNA-based diagnostics platform. Our initial investigation and development aims to diagnose the cause of sepsis in the fastest, most reliable and affordable way. We are working on providing the asset which patients need the most: time.

Neuroelectrics® is a digital brain health company that innovates at the intersection of neuroscience, physics, machine learning, and hardware. We have developed wireless EEG and tDCS/tACS/tRNS stimulation devices with up to 32 channels, amongst other products encompassing software and research services, with the purpose of monitoring and enhancing brain health.

At Quibim, we design pioneering tools that unlock imaging data to improve patient outcomes. Our main purpose is the application of AI techniques to medical images from MRI, CT, PET to unlock new data which can be transformed into actionable predictions for life sciences and providers.

Our #AI and #BigData based software assists radiologists in the detection and characterization of abdominal lesions on CT scans and MRIs. It also provides a prediction of the probability of each lesion to become cancer in the future, which is crucial to diagnose early-stage pancreatic cancer and to improve the life quality of patients